Homology Medicines (NASDAQ:FIXX) Trading Up 7.1%

Homology Medicines Inc (NASDAQ:FIXX)’s stock price was up 7.1% during mid-day trading on Monday . The stock traded as high as $17.18 and last traded at $17.14, approximately 421,756 shares changed hands during mid-day trading. An increase of 75% from the average daily volume of 240,548 shares. The stock had previously closed at $16.00.

Several research analysts recently issued reports on FIXX shares. HC Wainwright set a $36.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a research report on Tuesday, September 24th. FIX started coverage on shares of Homology Medicines in a research report on Thursday, October 31st. They issued a “market perform” rating for the company. Zacks Investment Research lowered shares of Homology Medicines from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. Oppenheimer started coverage on shares of Homology Medicines in a research report on Friday, November 1st. They issued a “market perform” rating for the company. Finally, Robert W. Baird started coverage on shares of Homology Medicines in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Homology Medicines has an average rating of “Hold” and an average price target of $31.40.

The stock has a market cap of $704.55 million, a price-to-earnings ratio of -8.57 and a beta of 0.14. The company’s 50-day moving average is $13.63 and its 200-day moving average is $17.60.

In other news, CEO Arthur Tzianabos sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $18.75, for a total transaction of $234,375.00. Following the completion of the sale, the chief executive officer now owns 140,005 shares of the company’s stock, valued at $2,625,093.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO W Bradford Smith sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $18.74, for a total transaction of $112,440.00. Following the sale, the chief financial officer now directly owns 6,000 shares of the company’s stock, valued at approximately $112,440. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,766 shares of company stock valued at $1,027,914. Company insiders own 33.40% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of FIXX. Aperio Group LLC acquired a new stake in shares of Homology Medicines during the second quarter worth approximately $34,000. Bank of Montreal Can bought a new stake in shares of Homology Medicines during the second quarter valued at approximately $40,000. Cubist Systematic Strategies LLC bought a new stake in shares of Homology Medicines during the second quarter valued at approximately $42,000. Marshall Wace LLP bought a new stake in shares of Homology Medicines during the first quarter valued at approximately $74,000. Finally, Royal Bank of Canada grew its stake in shares of Homology Medicines by 300.0% during the second quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock valued at $78,000 after purchasing an additional 3,000 shares during the last quarter. 71.06% of the stock is owned by institutional investors.

About Homology Medicines (NASDAQ:FIXX)

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Article: Investing in Dividend Stocks

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.